Advancing treatments for rare diseases together

Foundation

22May

EspeRare's 2023 Annual Report is available

Foundation, Esperare, Annual report
EspeRare's Annual Report for 2023 has just been published.
The report provides a comprehensive overview of Foundation's financial performance, strategic initiatives, and key achievements over the past year.
 
Click here to read our new Annual Report.
 
 
AR image
03Jan

NeoCare featured in the latest issue of Le Micromécanicien

Neocare, CHD, Foundation

Miniaturization and precision at the service of life. 

The development of medical devices requires not only the knowledge of medical experts, but also engineers and innovative technologies. The journal Le Micromécanicien, in its December edition, published an article on NeoCare - an innovative medical device aimed at protecting the heart and lungs of newborns with heart defects.
 
A great opportunity for a medtech to finalize the development, production and commercialization of NeoCare for congenital heart defects and to extend this technology to many other indications for which the control and regulation of vessel pressure is necessary, for example liver transplantation or major liver resection. 

To read the full article go to pages 30-31 on the following link: https://lemicromecanicien.ch/

About Micromécanicien:

Le Micromécanicien is a specialized, technical and industrial magazine dedicated to microtechnology. Microtechnology applies to a field that permeates practically the entire industrial sector, particularly in French-speaking Switzerland, with a strong presence in the Jura Arc.

20Apr

EspeRare's 2016 Annual Report is available

Foundation, Esperare, Annual report

 

EspeRare's Annual Report for 2016 has just been published.
The Annual Report highlights the foundation's achievements for 2016 and its financial statements.
 
Click here to read our new Annual Report.

 

27Feb

EspeRare's CEO in the spotlight in Biotech Finance

Esperare, Foundation, Interview, Caroline Kant, Journal, Finance

For its issue "Special rare diseases", the journal Biotech Finances has chosen to feature EspeRare's CEO, Caroline Kant.The interview summarises Caroline Kant's career path as well as EspeRare's aims, realizations and business plan, thereby informing finance and biotechs specialists of EspeRare's unique business model.

http://www.eei-biotechfinances.com/

16Apr

EspeRare was presented at the IRDiRC

Foundation, Esperare, Sharon Terry, IRDiRC

The EspeRare foundation has been presented by Sharon Terry at the International Rare Diseases Research Consortium (IRDiRC) in Dublin, on April 16th.

About IRDiRC: The International Rare Diseases Research Consortium (IRDiRC) was initiated by the European Commission and the US National Institutes for Health Research and launched in April 2011 to foster international collaboration in the rare diseases field. IRDiRC will team up researchers and organizations investing in rare diseases research in order to achieve two main objectives, namely to deliver 200 new therapies for rare diseases and means to diagnose most rare diseases by the year 2020.

View the programme

 View conference report

15Apr

Launch of the EspeRare Foundation

Foundation, Esperare, Rare diseases

Today we are proud to announce the launch of the EspeRare Foundation, a nonprofit organisation set up by three Merck Serono employees.

Geneva, Switzerland, April 15, 2013 – Merck Serono, a division of Merck, Darmstadt, Germany, today announced the launch of the EspeRare Foundation, a nonprofit organization set up by three Merck Serono employees, in the framework of the Merck Serono Entrepreneur Partnership Program (EPP). Merck Serono will donate an initial €2.8 million funding to the EspeRare Foundation. In addition, Merck Serono will transfer the rights of rimeporide, a compound previously developed for heart failure by Merck. The Foundation will investigate this compound in Duchenne Muscular Dystrophy (DMD), a lethal genetic rare disease affecting 1 in every 3 600 males.

Read the full press release here